Menu
Not yet recruiting NCT06979661

Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy

Early Phase I Interventional Lung Cancer Non Small Cell Lung Cancer Lung Cancer Recurrent

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Haystack™ ctDNA Assay.
Who it may be relevant to
Registry conditions: Lung Cancer, Non Small Cell Lung Cancer, Lung Cancer Recurrent. Basic parameters: 18 years — 90 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy (PORT) for Minimal Residual Disease (MRD) for Lung Cancer: the MRD-PORT Trial

Overview

Primary Objective: Evaluate the role of ctDNA positivity in decision making for postoperative therapy for non-small cell lung cancer. The plan for postoperative therapy will be declared after pathology report review and before the ctDNA result. We will assess if ctDNA result changed the planned therapy. Secondary Objectives: Evaluate personalized postoperative Chemo/ICPI/Targeted Therapies/Radiation Therapy in clearing ctDNA Evaluate the disease-free survival (DFS) and overall survival (OS) of stage II/III lung cancer patients with postoperative ctDNA positive status Exploratory Objective: Evaluate radiomics features based on serial CT thoracic CT scans to determine if radiomic features can be associated with ctDNA positivity/negativity.

Detailed description

This is a pilot, single-arm interventional study evaluating the use of the Haystack™ circulating tumor DNA (ctDNA) assay to guide postoperative radiation therapy (PORT) and systemic therapy decisions for patients with Stage II-III non-small cell lung cancer (NSCLC) who have undergone surgical resection. The study aims to assess whether ctDNA monitoring can effectively detect minimal residual disease (MRD) and improve post-surgical treatment strategies.

Interventions

  • Diagnostic test Haystack™ ctDNA Assay
    A personalized, tumor-informed circulating tumor DNA (ctDNA) test that analyzes blood samples to detect minimal residual disease (MRD) and guide postoperative treatment decisions for patients with Stage II-III non-small cell lung cancer (NSCLC) following surgical resection. The test results will help determine whether patients should receive postoperative radiation therapy (PORT) and/or systemic therapy adjustments.

Primary outcome measures

  • Detection of Circulating Tumor DNA (ctDNA) Post-Surgery [Time frame: Baseline, 2-4 weeks, 3 months, 6 months, and 12 months post-surgery]
Secondary outcome measures (3)
  • Progression-Free Survival (PFS) [Time frame: Up to 3 years post-surgery]
  • Overall Survival (OS) [Time frame: Up to 5 years post-surgery]
  • Change in ctDNA Levels Over Time [Time frame: Baseline, 2-4 weeks, 3 months, 6 months, and 12 months post-surgery]

Eligibility criteria

Inclusion criteria

  • Have provided signed informed consent for the trial
  • Aged ≥18 years at the time of informed consent
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Diagnosed with histologically confirmed Stage II-III NSCLC and undergone surgical resection of lung tumor
  • No active second cancers/malignancy
  • Patients that received preoperative therapy (including chemotherapy and immunotherapy or others) are eligible
  • Willing and able to comply with all aspects of the protocol
  • Standard of care therapy and methods as per institution and investigator discretion -

Exclusion criteria

Exclusion criteria

  • Discontinued treatment due to a Grade 3 or higher AEs with chemotherapy or immunotherapy or targeted therapy agent
  • With a history of another primary malignancy within the past 2 years that is considered an active malignancy by the enrolling physician.
  • Have known active CNS metastases and/or carcinomatous meningitis.
  • Have a history of (non-infectious) pneumonitis that required steroids or have current pneumonitis.
  • Have a history of interstitial lung disease.
  • Have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator. -

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Diagnostic

Study locations

United States · 1 center
  • Rutgers Cancer Institute — New Brunswick

Identifiers

NCT: NCT06979661 · 032411

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗